

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0154US1	Application No. 10/560,098
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1643
(37 CFR §1.98(b))			

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/LB/	25	JP11-500916	01/26/1999	Japan			Abstract only	
	26	JP 2002-543822	12/24/2002	Japan				
	27	JP 2004-086662	03/18/2004	Japan			Abstract only	
	28	JP 2003-515323	05/07/2003	Japan				
	29	WO 94/05690	03/17/1994	WIPO				
	30	WO 96/27011	09/06/1996	WIPO				
	31	WO 97/10354	03/20/1997	WIPO			English abstract	
	32	WO 00/069462	11/23/2000	WIPO				
	33	WO 01/036486	05/25/2001	WIPO				
	34	WO 2004/019966	03/11/2004	WIPO			English abstract	
	35	WO 04/111233	12/23/2004	WIPO			English abstract	
	36	WO 05/056604	06/23/2005	WIPO			English abstract	
	37	WO 2005/107784	11/17/2005	WIPO			English abstract	

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/LB/	38	ARNDT et al., "Generation of a highly stable, internalizing anti-DC22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma," <i>Int. J. Cancer</i> , 107(5):822-829 (2003)
	39	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310 (1990)
	40	CLACKSON et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)
	41	COCHLOVIUS et al., "Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells", <i>The Journal of Immunology</i> 165:888-895 (2000)
	42	DEJONGE et al., "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-DC3 x anti-idiotypic) induces long term survival of the murine BCL1 lymphoma model," <i>J. Immunol.</i> , 161(3):1454-1461 (1998)
	43	DESPLANCQ et al., "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)
	44	EIJSSINK et al., "Rational engineering of enzyme stability," <i>Journal of Biotechnology</i> , 113:105-120 (2004)

Examiner Signature /Lynn Bristol/	Date Considered 08/09/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	